- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Medovex Shares Details of $2.69 Million Offering and Private Placement
Medovex entered into definitive agreements with investors for the purchase and sale of 2,956,043 shares of common stocks.
Medovex (NASDAQ:MDVX) entered into definitive agreements with investors for the purchase and sale of 2,956,043 shares of common stocks.
As quoted in the press release:
The warrants will expire five years from the date of issuance. The non-brokered transaction resulted in net proceeds of approximately $2.69 million. The Company intends to use the net proceeds for working capital and other general corporate purposes.
Jarrett Gorlin, Medovex CEO, stated, “We are pleased to announce the closing of this non-brokered financing, priced at the market. Importantly as indicated in our Form 8K filed with the SEC on Friday, as a result of the offering, the Company had stockholders’ equity of more than $2.5 million as of the date of the filing. In addition, we are anxious and looking forward to sharing preliminary early results of multiple recently completed first in human cases for the DenerveX System, near term.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.